# The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.

> **NCT02710747** · PHASE4 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Heart Valve Disease
- Older Than 18-years-old
- Without Any Liver or Kidney Diseases

## Interventions

- **GENETIC:** CYP2C9;VKORC1

## Key facts

- **NCT ID:** NCT02710747
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2016-06
- **Final completion:** 2016-07
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710747, "The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02710747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*